Kane Biotech works with researchers on clinical plan to study revyve wound gel spray in military field care settings

• Revyve antimicrobial wound gel spray research was presented at the Military Health System Research Symposium on Aug. 3-5, 2026.
• Presentation highlighted potential use in military and prolonged field care, where access to advanced treatment can be delayed.
• Discussion centered on broad antimicrobial coverage, biofilm management, contactless application, and fit for complex wound cavities.
• Several researchers approached Kane Biotech to pursue additional clinical research evaluating revyve in military and complex wound settings.
• Kane is developing a clinical research plan, positioning military and government healthcare channels as a longer-term commercial opportunity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kane Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608250725PRIMZONEFULLFEED9815233) on August 25, 2026, and is solely responsible for the information contained therein.